Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
Hongyuan Lu, Qinbiao Wang, Xiaowen Jiang, Yanyun Zhao, Miao He, Minjie We. The Potential Mechanism of Cannabidiol (CBD) Treatment of Epilepsy in Pentetrazol (PTZ) Kindling Mice Uncovered by Multi-Omics Analysis. Molecules (Basel, Switzerland). vol 28. issue 6. 2023-03-29. PMID:36985783. |
the potential mechanism of cannabidiol (cbd) treatment of epilepsy in pentetrazol (ptz) kindling mice uncovered by multi-omics analysis. |
2023-03-29 |
2023-08-14 |
mouse |
Hongyuan Lu, Qinbiao Wang, Xiaowen Jiang, Yanyun Zhao, Miao He, Minjie We. The Potential Mechanism of Cannabidiol (CBD) Treatment of Epilepsy in Pentetrazol (PTZ) Kindling Mice Uncovered by Multi-Omics Analysis. Molecules (Basel, Switzerland). vol 28. issue 6. 2023-03-29. PMID:36985783. |
cannabidiol (cbd) is the main active ingredient in the cannabis plant used for treating epilepsy and related diseases. |
2023-03-29 |
2023-08-14 |
mouse |
Sumit Bansal, Mayur K Ladumor, Mary F Paine, Jashvant D Unadka. Drug metabolism and disposition: the biological fate of chemicals. 2023-03-27. PMID:36972999. |
cannabidiol (cbd) is available as a prescription oral drug that is indicated for the treatment of some types of epilepsy in children and adults. |
2023-03-27 |
2023-08-14 |
Not clear |
Jimmy Li, Cassandra C Areal, Dènahin Hinnoutondji Toffa, Daphné Citherlet, Charles Deacon, Didier Jutras-Aswad, Mark Robert Keezer, Dang Khoa Nguye. Use of non-medical cannabis in epilepsy: A scoping review. Frontiers in neurology. vol 14. 2023-03-23. PMID:36949852. |
use of non-medical cannabis in epilepsy: a scoping review. |
2023-03-23 |
2023-08-14 |
Not clear |
Jimmy Li, Cassandra C Areal, Dènahin Hinnoutondji Toffa, Daphné Citherlet, Charles Deacon, Didier Jutras-Aswad, Mark Robert Keezer, Dang Khoa Nguye. Use of non-medical cannabis in epilepsy: A scoping review. Frontiers in neurology. vol 14. 2023-03-23. PMID:36949852. |
the use of medical cannabis among people with epilepsy (pwe) has been garnering increasing interest. |
2023-03-23 |
2023-08-14 |
Not clear |
Dagmar Koethe, Cathrin Rohleder, Lutz Kracht, F Markus Lewek. Cannabidiol enhances cerebral glucose utilization and ameliorates psychopathology and cognition: A case report in a clinically high-risk mental state. Frontiers in psychiatry. vol 14. 2023-03-20. PMID:36937734. |
cannabidiol is a promising compound carrying an orphan drug approval for rare certain childhood epilepsy types and is under investigation as an antipsychotic compound with a new mechanism of action compared to existing antipsychotics. |
2023-03-20 |
2023-08-14 |
Not clear |
Darina Georgieva, James Langley, Katherine Hartkopf, Lisa Hawk, Amanda Margolis, Aaron Struck, Elizabeth Felton, David Hsu, Barry E Gida. Real-world, long-term evaluation of the tolerability and therapy retention of Epidiolex® (cannabidiol) in patients with refractory epilepsy. Epilepsy & behavior : E&B. vol 141. 2023-03-09. PMID:36893722. |
real-world, long-term evaluation of the tolerability and therapy retention of epidiolex® (cannabidiol) in patients with refractory epilepsy. |
2023-03-09 |
2023-08-14 |
Not clear |
Erica Braun, Francesca M Gualano, Prabha Siddarth, Eric Sega. Second-line cannabis therapy in patients with epilepsy. Clinical neurology and neurosurgery. vol 227. 2023-03-04. PMID:36870086. |
second-line cannabis therapy in patients with epilepsy. |
2023-03-04 |
2023-08-14 |
Not clear |
Antonella Riva, Gianluca D'Onofrio, Angelica Pisati, Roberta Roberti, Elisabetta Amadori, Friedrich Bosch, Carolina Fischinger Moura de Souza, Ashley Thomas, Emilio Russo, Pasquale Striano, Allan Baya. Cannabidiol Add-On in Glycosylphosphatidylinositol-Related Drug-Resistant Epilepsy. Cannabis and cannabinoid research. 2023-03-02. PMID:36862522. |
cannabidiol add-on in glycosylphosphatidylinositol-related drug-resistant epilepsy. |
2023-03-02 |
2023-08-14 |
Not clear |
Se Hee Kim, Han Som Choi, Chung Mo Koo, Bong-Rim Joo, Byung-Joo Park, Hae Kook Lee, Joon Soo Lee, Heung Dong Kim, Hoon-Chul Kan. Erratum: Effects of Cannabidiol on Adaptive Behavior and Quality of Life in Pediatric Patients With Treatment-Resistant Epilepsy. Journal of clinical neurology (Seoul, Korea). vol 19. issue 2. 2023-02-28. PMID:36854341. |
erratum: effects of cannabidiol on adaptive behavior and quality of life in pediatric patients with treatment-resistant epilepsy. |
2023-02-28 |
2023-08-14 |
Not clear |
b' George J\\xc3\\xaetc\\xc4\\x83, Bianca E \\xc5\\x90sz, Camil E Vari, Carmen-Maria Rusz, Amelia Tero-Vescan, Amalia Pu\\xc8\\x99ca\\xc8\\x9. Cannabidiol: Bridge between Antioxidant Effect, Cellular Protection, and Cognitive and Physical Performance. Antioxidants (Basel, Switzerland). vol 12. issue 2. 2023-02-25. PMID:36830042.' |
the literature provides scientific evidence for the beneficial effects of cannabidiol (cbd), and these effects extend beyond epilepsy treatment (e.g., lennox-gastaut and dravet syndromes), notably the influence on oxidative status, neurodegeneration, cellular protection, cognitive function, and physical performance. |
2023-02-25 |
2023-08-14 |
Not clear |
Danielle McDermott, Marielle L Darwin, Kirsten Fetrow, Ian Coulter, Kristal Biesecker, John A Thompso. Cannabis use patterns in drug-resistant and pharmacoresponsive epilepsy: Single tertiary referral center survey investigation. PloS one. vol 18. issue 1. 2023-01-27. PMID:36706124. |
cannabis use patterns in drug-resistant and pharmacoresponsive epilepsy: single tertiary referral center survey investigation. |
2023-01-27 |
2023-08-14 |
Not clear |
Danielle McDermott, Marielle L Darwin, Kirsten Fetrow, Ian Coulter, Kristal Biesecker, John A Thompso. Cannabis use patterns in drug-resistant and pharmacoresponsive epilepsy: Single tertiary referral center survey investigation. PloS one. vol 18. issue 1. 2023-01-27. PMID:36706124. |
this study sought to identify differences in cannabis use and perceptions about cannabis in mitigating seizure-related symptoms in patients with epilepsy, and to evaluate differences in these patterns between drug-resistant versus pharmacoresponsive epilepsy. |
2023-01-27 |
2023-08-14 |
Not clear |
Danielle McDermott, Marielle L Darwin, Kirsten Fetrow, Ian Coulter, Kristal Biesecker, John A Thompso. Cannabis use patterns in drug-resistant and pharmacoresponsive epilepsy: Single tertiary referral center survey investigation. PloS one. vol 18. issue 1. 2023-01-27. PMID:36706124. |
a collection of self-report surveys completed by patients with epilepsy (n = 76) were used to retrospectively compare differences in those with drug-resistant versus pharmacoresponsive epilepsy regarding 1) proportion who used cannabis, 2) frequency of use, 3) method of use, and 4) reason for use. |
2023-01-27 |
2023-08-14 |
Not clear |
Danielle McDermott, Marielle L Darwin, Kirsten Fetrow, Ian Coulter, Kristal Biesecker, John A Thompso. Cannabis use patterns in drug-resistant and pharmacoresponsive epilepsy: Single tertiary referral center survey investigation. PloS one. vol 18. issue 1. 2023-01-27. PMID:36706124. |
results from this study highlight the need for epilepsy providers to formally assess patients' perceptions and use of non-prescribed cannabis to inform clinical care decisions, particularly in the drug-resistant epilepsy population. |
2023-01-27 |
2023-08-14 |
Not clear |
Lyndsey L Anderson, Dilara A Bahceci, Nicole A Hawkins, Declan Everett-Morgan, Samuel D Banister, Jennifer A Kearney, Jonathon C Arnol. Heterozygous deletion of Gpr55 does not affect a hyperthermia-induced seizure, spontaneous seizures or survival in the Scn1a+/- mouse model of Dravet syndrome. PloS one. vol 18. issue 1. 2023-01-26. PMID:36701411. |
a purified preparation of cannabidiol (cbd), a cannabis constituent, has been approved for the treatment of intractable childhood epilepsies such as dravet syndrome. |
2023-01-26 |
2023-08-14 |
mouse |
Fabienne Kühne, Lena-Luise Becker, Thomas Bast, Astrid Bertsche, Ingo Borggraefe, Christian Malte Boßelmann, Jörg Fahrbach, Christoph Hertzberg, Nina A Herz, Martin Hirsch, Martin Holtkamp, Christine Janello, Gerhard Josef Kluger, Gerhard Kurlemann, Holger Lerche, Konstantin L Makridis, Felix von Podewils, Milka Pringsheim, Susanne Schubert-Bast, Juliane Schulz, Andreas Schulze-Bonhage, David Steinbart, Bernhard J Steinhoff, Adam Strzelczyk, Steffen Syrbe, Heike De Vries, Christiane Wagner, Johanna Wagner, Bernd Wilken, Christine Prager, Kerstin A Klotz, Angela M Kaind. Real world data on cannabidiol treatment of various epilepsy subtypes: a retrospective, multicenter study. Epilepsia open. 2023-01-24. PMID:36693811. |
real world data on cannabidiol treatment of various epilepsy subtypes: a retrospective, multicenter study. |
2023-01-24 |
2023-08-14 |
Not clear |
Cindy H T Yeung, Jessica L Beers, Klarissa D Jackson, Andrea N Edginto. Verifying in vitro-determined enzyme contributions to cannabidiol clearance for exposure predictions in human through physiologically based pharmacokinetic modelling. CPT: pharmacometrics & systems pharmacology. 2022-12-21. PMID:36540909. |
cannabidiol (cbd) is approved for treatment of seizures associated with two forms of epilepsy that become apparent in infancy or early childhood. |
2022-12-21 |
2023-08-14 |
human |
Jerzy P Szaflarski, Orrin Devinsky, Merrick Lopez, Yong D Park, Pilar Pichon Zentil, Anup D Patel, Elizabeth A Thiele, Robert T Wechsler, Daniel Checketts, Farhad Sahebka. Long-term efficacy and safety of cannabidiol in patients with treatment-resistant epilepsies: 4-year results from the expanded access program. Epilepsia. 2022-12-20. PMID:36537757. |
long-term efficacy and safety of cannabidiol in patients with treatment-resistant epilepsies: 4-year results from the expanded access program. |
2022-12-20 |
2023-08-14 |
Not clear |
Jerzy P Szaflarski, Orrin Devinsky, Merrick Lopez, Yong D Park, Pilar Pichon Zentil, Anup D Patel, Elizabeth A Thiele, Robert T Wechsler, Daniel Checketts, Farhad Sahebka. Long-term efficacy and safety of cannabidiol in patients with treatment-resistant epilepsies: 4-year results from the expanded access program. Epilepsia. 2022-12-20. PMID:36537757. |
cannabidiol (cbd) expanded access program (eap), initiated in 2014, provided add-on cbd to patients with treatment-resistant epilepsy (tre) at 35 us epilepsy centers. |
2022-12-20 |
2023-08-14 |
Not clear |